öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º×ó³¯êÍ
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º375

ËùÊôԺУ£ºÄÏ»ª´óѧ
ËùÊôԺϵ£ººþÄÏÊ¡Ö×ÁöÒ½Ôº
Ö°³Æ£ºÖ÷ÈÎҽʦ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÍâ¿Æѧ
Ñо¿ÁìÓò£º
Ñо¿ÁìÓò£º [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºzuochaohui@vip.sina.com


¸öÈ˼òÊö :
×ó³¯êÍ£¬Ô­·¢ÐԸΰ©×ÛºÏÖÎÁÆ»úÖÆÓ¦ÓõÄÑо¿£¬ºþÄÏÊ¡¿Æ¼¼Ìü£¬ºþÄÏÊ¡¿Æ¼¼½ø²½½±£¬ÈýµÈ½±£¬2013¡£×ó³¯êÍ£¬ºþÄÏÊ¡Õþ¸®ÌØÊâ½òÌù£¨Ê׽죩£¬ºþÄÏÊ¡Õþ¸®£¬2013¡£×ó³¯êÍ£¬ºþÄÏÊ¡ÈËÊÂÌü£¬ºþÄÏÊ¡ÐÂÊÀ¼Í121È˲Ź¤³ÌÈý²ã´ÎÈËÑ¡£¬2012

¿ÆÑй¤×÷ :
2008.10¡ªÖÁ½ñ, ÖÐÄÏ´óѧÏæÑÅҽѧԺ¸½ÊôÖ×ÁöҽԺθʮ¶þÖ¸³¦ÒÈÏÙÍâ¿Æ¼°¸Î°©×ª»¯Ò½Ñ§ÁªºÏÑо¿ÖÐÐÄ£¨ºþÄÏ´óѧ.Ö×ÁöÒ½Ôº£©£¬Ö÷ÈÎҽʦ£¨ÆƸñ½úÉý£©(ÆäÖÐÓÚ2008.01¡ª2008.12£¬ÏæÎ÷ÍÁ¼Ò×å×ÔÖÎÖݹÅÕÉÏØ£¬¿Æ¼¼·öƶ¹¤×÷)¡£2004.07¡ª2008.09, ÖÐÄÏ´óѧÏæÑÅҽѧԺ¸½ÊôÖ×ÁöÒ½Ôº¸¹²¿Íâ¿Æ£¬¸±Ö÷ÈÎҽʦ.¿ÆÊÒ¸±Ö÷ÈΡ£1996.07¡ª1998.09£¬ºþÄÏͨµÀÏØÈËÃñÒ½ÔºÍâ¿Æ£¬×¡ÔºÒ½Ê¦ ÆÚ ¿¯-> Zhou K, Xia M*, Tang B, Yang D, Liu N, Tang D, Xie H, Wang X, Zhu H, Liu C, Zuo C*, Isolation and comparison of mesenchymal stem cell like cells derived from human gastric cancer tissues and corresponding ovarian metastases, Mol Med Rep, 2016, 13(1): 1788-1794. (IF:1.554) ÆÚ ¿¯-> Lei X, Li YF, Chen GD, Ou DP, Qiu XX, Zuo CH, Yang LY*, Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma, Oncotarget, 2015, 6(38): 40622-40641. (IF:6.359)ÆÚ ¿¯-> Quan H, Zuo C, Li T, Liu Y, Li M, Zhong M, Zhang Y, Qi H, Yang M*, Electrochemical detection of carcinoembryonic antigen based on silver nanocluster. horseradish peroxidase nanocomposite as signal probe, Electrochimica Acta, 2015, 176: 893¨C897. (IF: 4.504)ÆÚ ¿¯-> Xiao H, Zhang B, Mei B, Zuo C, Wei G, Wang R, Zhang B, Chen X*, Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation. Medicine (Baltimore), 2015, 94(7): e495. (IF: 4.867)ÆÚ ¿¯-> Zuo C*, Qiu X, Liu N, Yang D, Man X, Liu J, Wang X, Zhu H, Xie H, Xie P, Burns M, Liu C*, Interferon-¦Á and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma, Exp Cell Res, 2015, 32(2): 316-326.£¨IF: 3.872£©ÆÚ ¿¯-> Zuo CH*, Xia M*, Liu JS, Qiu XX, Lei X, Xu RC, Liu HC, Li JL, Li YG, Li QL, Xiao H, Hong Y, Wang XH, Zhu HZ, Wu QF, Burns M, Liu C, Transcatheter Arterial Chemoembolization Combined with Interferon-¦Á is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection, Asian Pac J Cancer Pre, 2015, 16 (1): 245¨C251. (IF: 2.514£©ÆÚ ¿¯-> Zuo CH*, Xia M, Wu QF, Zhu HZ, Liu JS, Liu C*, Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review), Oncol Lett, 2015, 9 (2): 527-534.£¨IF: 1.554£©ÆÚ ¿¯-> Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C, Zuo C*, ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma, Int J Clin Exp Med, 2015, 8(10): 17140-50. (IF:1.472)ÆÚ ¿¯-> Xiao H, Xie P, Zhou K, Qiu X, Hong Y, Liu J, Ouyang Y, Ming T, Xie H, Wang X, Zhu H, Man X*, Zuo C*, Clavien-Dindo classification and risk factors of gastrectomy-related complications: an analysis of 1049 patients, Int J Clin Exp Med, 2015, 8(5): 8262-8268.£¨IF: 1.472£©ÆÚ ¿¯-> Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, Hu J, Wang L, Zhou Z, Liu B, Tan D, Guan Y, Zhu H*, Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line, Proc Natl Acade Sci U S A, 2014, 111(13): e1264-1273. (IF:9.674)ÆÚ ¿¯-> Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, Zhu H*, miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT, Oncotarget, 2014, 5(12): 4010-4012. (IF:6.359)ÆÚ ¿¯-> Zuo CH*, Qiu XX, Ouyang YZ, Zhang D, Xiao H, Mo SC, Tan CQ, Tang M, Zhu HZ, Mesohepatectomy for the treatment of patients with centrally located hepatocellular carcinoma, Mol Clin Oncol, 2014, 12(5): 833-838. ÆÚ ¿¯-> Zuo CH*, Xie HL, Liu JS, Qiu XX, Lin JG, Xiao H, Qin A, Characterization of lymph node metastasis and its clinical significance in the surgical treatment of gastric cancer, Mol Clin Oncol, 2014, 12(5): 821-826. ÆÚ ¿¯-> Huang L, Wu C, Yu D, Wang C, Che X, Miao X, Zhai K, Chang J, Jiang G, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, Zhang X, Zhou Y, Yu X, Dai W, Li Z, Shen H, Liu L, Chen Y, Zhang S, Wang X, Liu Y, Sun M, Cao W, Gao J, Ma Y, Zheng X, Cheung ST, Jia Y, Tan W, Wu T*, Lin D*, Identificantion of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer, Carcinogenesis, 2013, 34(5): 1001-1005. (IF: 5.334) ÆÚ ¿¯-> Wu C, Miao X, Huang L, Che X, Jiang G, Yu D, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, Zhang X, Zhou Y, Yu X, Dai W, Li Z, Shen H, Liu L, Chen Y, Zhang S, Wang X, Zhai K, Chang J, Liu Y, Sun M, Cao W, Gao J, Ma Y, Zheng X, Cheung ST, Jia Y, Xu J, Tan W, Zhao P, Wu T, Wang C*, Lin D*, Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations, Nature Genetics, 2011, 11(12): 16-23. (IF: 29.352)ÆÚ ¿¯-> Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H*, Innate host response in primary human hepatocytes with hepatitis C virus infection, Plos One, 2011, 6(11): 16-18. (IF:3.234)ÆÚ ¿¯-> Ф»ª£¬ÐíÈô²Å£¬Áõº®´º£¬ÀÁ¼£¬ÓàÖ¾Ô¨£¬Å·ÑôÓÀÖÒ£¬ÇñÏþê¿£¬ÀîÇåÁú£¬ÀîÓÀ¹ú£¬Ö캣Õ䣬лÎı룬лº£Áú£¬µ¥ºº¹ú£¬Áõ¾°Ê«£¬×ó³¯êÍ*£¬ÉäƵÏûÈÚÁªºÏË÷À­·ÆÄáºÍ¸ÉÈÅËØÖÎÁƸ´·¢ÐԸΰ©µÄÁÙ´²Ñо¿£¬ÖйúÏÖ´úÊÖÊõѧÔÓÖ¾£¬2015£¬19£¨5£©£º338 ~ 342.ÆÚ ¿¯-> ÇñÏþê¿,ºéÔ´,ÖÜçûåû,ÏÄÂù,Ê¢ÐÂÒÇ,ÌƲ¨,ÍõСºì,Ö캣Õä,Áõ¾°Ê«*, ×ó³¯êÍ*£¬¦Á-¸ÉÈÅËغÍCOX-2ÒÖÖƼÁ¶ÔÈ˸ΰ©Ï¸°ûµÄÉú³¤ÒÖÖÆ×÷Óã¬ÖйúÏÖ´úÊÖÊõѧÔÓÖ¾£¬2014£¬18£¨5£©£º321 ~ 326.ÆÚ ¿¯-> Ф»ª£¬Å·ÑôÓÀÖÒ£¬ÌÀÃ÷£¬ÌÆÎÀ£¬ÅËÊï¹â£¬Òü±ò£¬ÂÞÍþ£¬È¨»¢£¬ÇñÏþê¿£¬×ó³¯êÍ*£¬Î§ÊÖÊõÆÚÊäѪÓëθ°©¸ùÖÎÊõºó²¢·¢Ö¢µÄ¹Øϵ£¬ÖлªÒ½Ñ§ÔÓÖ¾£¬2014, 94£¨10£©£º751 ~ 754.ÆÚ ¿¯-> Ф»ª£¬×ó³¯êÍ*£¬Å·ÑôÓÀÖÒ£¬ÌÀÃ÷£¬ÌÆÎÀ£¬ÅËÊï¹â£¬Òü±ò£¬ÂÞÍþ£¬È¨»¢£¬ÇñÏþê¿£¬Î¸°©¸ùÖÎÊõºó·Î²¿¸ÐȾµÄΣÏÕÒòËØ·ÖÎö£¬ÖлªÒ½Ñ§ÔÓÖ¾£¬2014£¬ 94£¨42£©£º3210 ~ 3213.ÆÚ ¿¯-> Ф»ª£¬Å·ÑôÓÀÖÒ£¬ÌÀÃ÷£¬ÌÆÎÀ£¬ÅËÊï¹â£¬Òü±ò£¬ÂÞÍþ£¬È¨»¢£¬ÇñÏþê¿£¬×ó³¯êÍ*,θ°©¸ùÖÎÊõºó¸¹Ç»¸ÐȾµÄΣÏÕÒòËØ·ÖÎö,ÖлªÒ½Ñ§ÔÓÖ¾£¬2013, 93£¨40£©£º3211 ~ 3214.ÆÚ ¿¯-> Ф»ª£¬ÅËÊï¹â£¬Òü±ò£¬ÂÞÍþ£¬È¨»¢£¬ÇñÏþê¿£¬ºéÔ´£¬×ó³¯êÍ*£¬Î¸°©¸ùÖÎÊõºó²¢·¢Ö¢µÄClavien-Dindo·Ö¼¶»úΣÏÕÒòËØ·ÖÎö,ÖлªÒ½Ñ§ÔÓÖ¾, 2013£¬93£¨46£©£º3667 ~ 3670.ÆÚ ¿¯-> Ф»ª£¬×ó³¯êÍ*, ¾Ö²¿½øÕ¹ÆÚθ°©ÁªºÏÔàÆ÷ÇгýµÄÑо¿½øÕ¹, ÖлªÁÙ´²Ò½Ê¦ÔÓÖ¾£¨µç×Ӱ棩£¬2013, 7£¨15£©: 7163 ~ 7165.ÆÚ ¿¯-> Ф»ª£¬Å·ÑôÓÀÖÒ£¬ÌÀÃ÷£¬ÌÆÎÀ£¬ÅËÊï¹â£¬Òü±ò£¬ÂÞÍþ£¬È¨»¢£¬ÇñÏþê¿£¬×ó³¯êÍ*, θ°©¸ùÖÎÊõºó¸¹Ç»¸ÐȾµÄ²¡Ô­Ñ§·ÖÎö£¬ÖлªÊµÑéºÍÁÙ´²¸ÐȾ²¡ÔÓÖ¾£¨µç×Ӱ棩£¬2013£¬7£¨6£©: 887 ~ 889.ÆÚ ¿¯-> ×ó³¯êÍ£¬ÕÅÀí£¬Å·ÑôÓÀÖÒ£¬ÌÀ Ã÷£¬ÁÖ¾¢¹Ú£¬Ð¤ »ª£¬ÇñÏþê¿£¬ÅËÊï¹â, Òü ±ò£¬ÂÞ Íþ£¬Àî¿¡¾ü£¬Ö캣Õ䣬¾Ö²¿½øÕ¹ÆÚθ°©ÁªºÏÔàÆ÷ÇгýÊõµÄÁÙ´²·ÖÎö£¨¸½93Àý±¨¸æ£©£¬Öйú°©Ö¢·ÀÖÎÔÓÖ¾£¨µç×Ӱ棩£¬2013, 5£¨1£©£º61 ~ 64.ÆÚ ¿¯-> ×ó³¯êÍ£¬Å·ÑôÓÀÖÒ£¬Ö캣Õ䣬Īʤ´¨£¬Ì·´ºÆ½­²ªÄ꣬ÌÆÎÀ£¬ÌÀÃ÷£¬ÂÞ½¨ºì£¬ Ô­·¢ÐÔ´ó¸Î°©µÄÍâ¿ÆÖÎÁÆ£¬ÖйúÆÕͨÍâ¿ÆÔÓÖ¾£¬2012£¬24£¨1£©£º16 ~ 18.ÆÚ ¿¯-> ×ó³¯êÍ£¬ÏòÔƸ»£¬ÏòÒÕ£¬Ê·°Ù¸ß£¬ÎâµÇ¿Æ£¬µËѧ»Ô£¬ÑîÉÙ»ª£¬ÁÖ¾¢¹Ú£¬ÏæÎ÷ÍÁ¼Ò×åÃç×å×ÔÖÎÖݹÅÕÉÏغÍÓÀ˳ÏØ1992¡«2006ÄêÔ­·¢ÐԸΰ©ËÀÍöµ÷²édzÎö£¬ÖйúÏÖ´úÊÖÊõѧÔÓÖ¾£¬2012£¬16£¨1£©£º15 ~ 18.ÆÚ ¿¯-> ×ó³¯êÍ£¬ÁÖ¾¢¹Ú£¬Ö캣Õ䣬ÒÈÏÙ°©×ÛºÏÖÎÁƵĽøÕ¹£¬ÁÙ´²Ò½Ñ§¹¤³Ì, 2012£¬19(9)£º1623~1625.ÆÚ ¿¯-> ×ó³¯êÍ£¬Å·ÑôÓÀÖÒ£¬ÌÀÃ÷£¬ÌÆÎÀ£¬ÁÖ¾¢¹Ú£¬Ö캣Õ䣬θ°©µÄ×ÛºÏÖÎÁƵĽøÕ¹£¬ÖлªÆÕÍâÊÖÊõѧÔÓÖ¾£¨µç×Ӱ棩£¬2012£¬6£¨3£©£º55 ~ 59.ÆÚ ¿¯-> ×ó³¯êÍ£¬Å·ÑôÓÀÖÒ£¬ÄªÊ¤´¨£¬ÚÈÖÒÓÑ£¬ÖÜÏþ£¬ÍòÄܱó£¬ÍõÐļû£¬ÒÈÍ·°©ÖÎÁƵķÖÎö£¬ÖлªÖ×ÁöÔÓÖ¾£¬2011£¬28£¨4£©£º319 ~ 321.ÆÚ ¿¯-> ×ó³¯êÍ£¬ÀîÓÀ¹ú£¬»·ÑõºÏø-2ÒÖÖƼÁÓë¸Îϸ°û°©µÄ¹Øϵ£¬¸¹²¿Íâ¿Æ£¬2010£¬23£¨1£©£º51 ~ 52ÊÚȨ·¢Ã÷רÀû1¡¢Zhu H, Zuo C, Wang X, Yang D and Liu N, A human liver cancer cell line HLCZ01 and its application, PCT.CN2013.075459, US**(ÕýÔÚÉêÇëÃÀ¹úרÀû)£»2¡¢Zhu H, Zuo C, Wang X, Yang D and Liu N, HUMAN HEPATOMA CELL LINE HLCZOI AND USES THEREOF, AL AT BE BG CH CY CZDE DK EE IS IT LI LT LU LV MC MK MT NL NO TR ES FI FR GB GR HR HU IE PL PT RO RS SE SI SK SM TR(Å·ÃË)£¬**.4 - 1402i ** (Å·ÃËרÀû)£»3¡¢Ö캣Õ䣬×ó³¯êÍ£¬ÍõСºì£¬Ñî´óÈÙ£¬ÁõÄîÀñ£¬Ò»ÖÖÈ˸ΰ©ÏµHLCZ01¼°ÆäÓ¦Óã¬2014.10.12£¬Öйú£¬×¨ÀûºÅ£ºZL**8.4.£¨ÒÑÊÚȨ£© ºþÄÏÊ¡¿¹°©Ð­»áÒÈÏÙ°©öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱÖ÷ÈÎίԱ£¬ºþÄÏʡҽѧ»áÏû»¯µÀÖ×ÁöÍâ¿Æѧ×é×鳤¡£ÖйúÇàÄê¿Æ¼¼¹¤×÷ÕßЭ»á»áÔ±, Öйú¿¹°©Ð­»áµ¨µÀ¶ñÐÔÖ×ÁööλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£ÎñίԱÖйúÒ½ÁƱ£½¡¹ú¼Ê½»Á÷´Ù½ø»áÒÈÏÙ²¡·Ö»á¸±Ö÷ÈÎίԱµÈ¡£¹ú¼Êθ°©Ð­»á»áÔ±ÃÀ¹ú°©Ö¢Ñо¿Ð­»á»áÔ±¡£ÖлªÒ½Ñ§»áÖ×Áöѧ»á¸Î°©Ñ§×éίԱÖйúҽʦЭ»áÖ×ÁöÍâ¿ÆҽʦöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬Öйú¿¹°©Ð­»áµ¨µÀ¶ñÐÔÖ×ÁööλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£ÎñίԱÖйú¿¹°©Ð­»á¸Î°©öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ 1¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê¿Æѧ»ù½ðÏîÄ¿£¬**£¬¹ÇËèÖмä³äÖʸÉϸ°û·ÖÃÚµÄexosomeÖÐmiR-221ÔÚθ°©Âѳ²×ªÒÆÖеÄ×÷Óü°·Ö×Ó»úÖÆÑо¿£¬ 2016.01-2018.12£¬ 18ÍòÔª£¬ÔÚÑУ¬²Î¼Ó¡£2¡¢ºþÄÏÊ¡2015Äê¸ß²ã´Î¼±Ðè½ôȱÈ˲ųö¹ú£¨¾³£©ÑÐÐÞѧÊõ·ÃÎʽ»Á÷×ÊÖúÏîÄ¿£¬Î¸Ê®¶þÖ¸³¦ÒÈÏÙÖ×Áö»úÆ÷È˸¨ÖúÖÎÁÆ£¬ 2015.01-2017.12£¬5ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö¡£3¡¢ºþÄÏÊ¡·¢¸Äί2015ÄêÑз¢ÏîÄ¿£¬ºþÄÏÊ¡Î÷²¿µØÇøÍÁ¼Ò×å¡¢Ãç×åºÍ¶±×åµÈÉÙÊýÃñ×å¾ÓÃñÏû»¯µÀÖ×ÁöÆղ鼰×ÛºÏÖÎÁƺÍÔ¤·ÀµÄϵͳÑо¿£¬ 2015.10-2019.12£¬30ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö¡£4¡¢ºþÄÏÊ¡×ÔÈ»»ù½ð×ÊÖúÏîÄ¿£¬2015JJ6063£¬MicroRNA°ÐÏòµ÷¿ØEMS1ÔÚθ°©ÉÏƤ¼äÖÊת»¯ÖеķÖ×Ó»úÖÆÑо¿£¬2015.01-2017.12£¬4ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö¡£5¡¢ºþÄÏÊ¡ÎÀÉúÌü¿ÆÑÐÏîÄ¿£¬ B2014-116£¬COX-2ÒÖÖƼÁºÍÌ漪°Â¶Ôθ°©Âѳ²ÌØÒìÐÔתÒƵÄÉú³¤ºÍѪ¹ÜÉú³ÉЭͬÒÖÖÆ×÷ÓõÄÌåÄÚÍâʵÑ飬2015.01-2016.12£¬2ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö¡£6¡¢ºþÄÏÊ¡³¤É³ÊеÚÈýÅú¿Æ¼¼¼Æ»®ÏîÄ¿£¬K**-31£¬COX-2ÒÖÖƼÁºÍ¦Á-IFN°ÐÏòµ÷¿ØEMS1ÔÚ¸Îϸ°û°©ÉÏƤ¼äÖÊת»¯ÖеķÖ×Ó»úÖÆÑо¿£¬2013.01-2015.12£¬20ÍòÔª£¬ÒѽáÌ⣬Ö÷³Ö 1¡¢×ó³¯êÍÖ÷±à£¬³£¼ûÖ×ÁöÔ¤·ÀºÍÖÎÁÆ֪ʶÎʴ𣬳¤É³£ººþÄÏ¿Æѧ¼¼Êõ³ö°æÉ磬210ǧ×Ö£¬2016.2¡¢Áõ¾°Ê«£¬ÖÜÏþ£¬Áº½£Æ½Ö÷±à£¬³£¼ûÖ×ÁöÕïÁƲßÂÔ£¬×ó³¯êÍ£¬ºø¸¹²¿°©Íâ¿ÆÖÎÁÆ£¨µÚÊ®½Ú£©£¬Ê®¶þÖ¸³¦Ö×ÁöÍâ¿ÆÖÎÁÆ£¨µÚÊ®¾Å½Ú£©£¬Î¸°©Íâ¿ÆÖÎÁÆ£¨µÚ¶þÊ®½Ú£©£¬º£¿Ú£ºº£Äϳö°æÉ磬595ǧ×Ö£¬2015.3¡¢ÁõµÂÅ࣬ ³Âó㬰͵ÂÄ꣬ԬÖÓÖ÷±à£¬ÖлªÒ½Ñ§°Ù¿ÆÈ«Ê飨¹ú¼ÒÖص㹤³Ì£©£¬×ó³¯êÍ£¬ÒÈÏÙ°©Íâ¿ÆÖÎÁƼ°Î¸°©Íâ¿ÆÖÎÁÆ£¬±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬1.5ÒÚ×Ö£¬2014.4¡¢ÖÜÏþ£¬²ÜÒêÁÖ£¬ ºú±þÇ¿Ö÷±à£¬ Ö×ÁöÕûÐÎÍâ¿Æѧ£¬ÖÜÏþ£¬×ó³¯êÍ£¬Ö×ÁöÕûÐÎÍâ¿ÆµÄÄ¿±êºÍÖÎÁÆÔ­Ôò£¨µÚÈý½Ú£©£¬×ó³¯êÍ£¬ÖÜÏþ£¬Ö×ÁöÕûÐÎÍâ¿ÆµÄÖ×ÁöÕï¶Ï¼°TNM·ÖÆÚ£¨µÚËĽڣ©£¬×ó³¯êÍ£¬Áº½£Æ½£¬ÎÞ¾úÖÎÁƵÄÔ­Ôò£¨µÚÆß½Ú£©£¬º¼ÖÝ£ºÕã½­¿Æѧ³ö°æÉ磬87Íò×Ö£¬2013.

½ÌÓý±³¾° :
2014.01-2015.03£¬ÃÀ¹ú·ðÂÞÀï´ï´óѧҽѧԺ£¬ShandsÒ½Ôº°©Ö¢ÖÐÐIJ¡Àí¡¢ÃâÒß¡¢ÊµÑéҽѧϵ£¬²©Ê¿ºó¡£2013.04, ÃÀ¹úµÂ¿ËÈø˹ÖÝ´óѧ¸½ÊôM.D°²µÂÉ­°©Ö¢Ñо¿ÖÐÐÄ,½øÐ޲ιÛѧϰ¡£2012.05¡ª2013.12, »ªÖпƼ¼´óѧҽҩÎÀÉú¹ÜÀíѧԺEMHAÒ½Ôº¹ÜÀíÑÐÐÞ°à,Ñо¿Éú£¨ÒµÓࣩ¡£2012.03¡ª2012.04£¬Ð¼ÓƹúÁ¢Ò½Ñ§ÔºÒ½Ôº¹ÜÀíϵ£¬½øÐÞѧϰ¡£2007.03¡ª2007.09, ¶þ¾üÒ½´óѧÉϺ£¶«·½¸Îµ¨Íâ¿ÆÒ½Ôº£¬½øÐÞѧϰ¡£2009.05¡ª2009.08£¬ÉϺ£½»Í¨´óѧ¸½ÊôÈð½ðҽԺ΢´´ÖÐÐÄ£¬½øÐÞѧϰ¸¹Ç»¾µ¼¼Êõ¡£2001.09¡ª2004.07,ÖÐÄÏ´óѧÏæÑÅҽѧԺ, Íâ¿Æѧ²©Ê¿Ñо¿Éú¡£1998.09¡ª2001.07,¹ãÎ÷Ò½¿Æ´óѧÑо¿ÉúÔº£¬Ö×ÁöÍâ¿Æѧ˶ʿÑо¿Éú¡£1991.09¡ª1996.07,ºþÄϺâÑôҽѧԺ£¨½ñÄÏ»ª´óѧ£©ÁÙ´²Ò½Ñ§Ïµ£¬´óѧ±¾¿Æѧʿ